"Hey, it's still impossible to completely cure cancer. It can only cure it, only treat the symptoms, not the root cause."

Looking at Jiang Jun who was actively rehabilitating, Yun Heng was still a little dissatisfied. Although gene editing technology helped him survive, it could only last for ten years, and there was only a 60% chance of living for ten years, and there was a 40% chance of death within ten years because he could not control the spread of cancer.

Even if it is early detection and early treatment, it can only ensure an 80% survival rate in 20 years. If it is higher than 20 years, the survival rate will drop rapidly.

It sounds like 20 years is long, but it is true for middle-aged and elderly patients, but for a young man in his twenties, who is just over 20 years old, is it still cruel?

There are many factors that need to be considered in cancer survival rate, including diagnosis, treatment, prognosis, regular examinations, etc., which will affect the survival rate. The survival rates of different cancers in each country are different.

To give an extreme example, acute lymphocytic leukemia in children, is a relatively acute cancer with a fast onset and a short median period.

However, in Canada and the United States, the five-year survival rate of patients with this disease exceeds 90%. Even in Asian countries, countries with relatively developed medical standards such as Singapore, South Korea, Israel and Japan, the five-year survival rate is between 80% and 89%.

In China, the 5-year survival rate of acute lymphocytic leukemia in children is not only significantly lower than that of developed European countries, but is at the last place even in Asia. The survival rate is less than 60%, which is at the lowest level worldwide. Without reflection, why is this?

In addition, the 5-year survival rate of colon cancer in my country is at the lower and lower level among Asian countries and regions, and the 5-year survival rate of breast cancer is at the middle level in Asian countries and regions.

The five-year survival rate of more malignant esophageal cancer, gastric cancer and colorectal cancer still needs to be worked hard. As the top five cancer deaths in my country, the five-year survival rate of these cancers is basically not as good as our neighbors, Japan and South Korea.

The five-year survival rate of esophageal cancer is only 29%, among which rectal cancer is the highest, and it is only 56.9%.

The survival rate of liver cancer and even five-years is only 11%, pancreatic cancer 10%, adult leukemia 25%, and lung cancer 20%!

In addition to cancers with better treatment effects such as breast cancer, colorectal cancer, and cervical cancer, the 10-year survival rate can reach 90%. If early detection and treatment are detected, 70% of women can regain their health.

Most of the remaining cancers have less than 60% survival rates in five years!

However, the use of Yunheng's gene editing technology has enabled patients in the middle and late stages of glioblastoma to increase the original 10% survival rate of 3 years to 60% in 10 years!

It can also increase the survival rate of early glioblastoma patients to 80% in 10 years!

This is already a very remarkable achievement. Some expensive targeted drugs that act on the genetic level can only achieve similar inhibitory effects.

And that kind of targeted drug needs to be customized and produced based on the patient's genes, and a course of treatment costs hundreds of thousands of dollars!

The genetic programming targeted drug produced by Yun Heng and others in the laboratory only costs only 10,000 or 20,000 yuan. Even if the depreciation of scientific research equipment is added, the cost will not exceed 50,000 yuan!

Of course, the hundreds of millions of R&D funds spent are still not included.

But the R&D funding is already very low.

According to statistics from the WHO, the research and development cycle of a new drug takes an average of 15 years and US$5.5 billion in research and development funds.

The visual prosthesis device project jointly established by Wang Jia and him has no mature theoretical support in the scientific research community and no reliable visual perception application tools. Everything has to start from scratch, and the progress is much slower than Yun Heng and others.

On Wang Jia's side, the entire project team works overtime every day, and the project progress has just been completed. There is no clue about the real research and development.

Yun Heng, who was launched at the same time, has even been in clinical trials!

The main reason is that in addition to Chen Changan's support, Yun Heng has various gene editing paper data, as well as some advanced theoretical knowledge, and the CRISPRCas9 gene programming system has been in public for more than ten years and has been studied by the scientific community for more than ten years.

Yun Heng was like standing on the shoulders of giants and moving forward. In addition, he was indeed very strong in scientific research ability, and Qian Zhongsen, a scientific research talent who was also not inferior to him, joined, so he was lucky enough to create this set of cancer treatment technology based on the Cas9 gene programming system.

He himself knew that being able to achieve this level is the best achievement in human gene editing.

If you want to use gene editing to completely eliminate 100% of the human body's cancer cells and ensure that the cancer does not recur and that the cancer will be eliminated when it appears, the current medical level still cannot do this.

Of course, it is not that gene editing technology cannot completely cure cancer. Yun Heng can use gene editing technology to eliminate 80% of Jiang Jun's cancer cells at one time, which means that this technology is very correct and the idea is no problem.

However, it is not possible to allow the Cas9 gene to identify every cancer cell 100% and not to let go of any fish that misses the net.

As long as it cannot be completely eliminated, even if 99% of the cancer cells are eliminated, the remaining 1% can still continue to proliferate in the human body.

At present, it can only inhibit the growth of cancer cells and cannot completely eliminate cancer cells.

"The researchers at the research center should not leave them idle, continue to move, and enter cancer cells with higher malignancy such as esophageal cancer, gastric cancer, colorectal cancer, pancreatic cancer, lung cancer, liver cancer into the interval area of ​​our CRISPR sequence group as soon as possible to blacklist these cancer cells."

"This is the order given by Mr. Chen, allowing us to conduct clinical trials on more cancers as soon as possible. Otherwise, if we can only treat glioblastoma, a cancer, although it is still very excellent, its application scope is too narrow, and it is no different from those high-end targeted drugs."

"If we don't do it, we need to do it. If we want to do it, we need to make the best and best products of our similar products!"

Yun Heng smiled disdainfully and said contemptuously: "Only the rich among the rich can use those expensive gene targeted drugs. Even if the inhibitory effect on cancer is very good, how many people can be saved?"

"More cancer patients are in a situation where they cannot afford targeted drugs and have no money to treat chemical radiotherapy."

"The five-year survival rate of cancer patients in China is generally lower than that of developed countries in Europe and the United States. A large part of the reason is that they cannot afford to treat it. The cancer drugs sold in developed countries in Europe and the United States are too expensive!"

"The country is now in urgent need of a targeted drug that is more affordable and effective in treating cancer!"

"We have to break the routine. In the past, a targeted drug could only treat one cancer, which was too cumbersome."

"If there is a targeted drug that can have therapeutic effects on most cancers, which is more suitable for circulation and promotion!"

"After all, the more versatile the product, the easier it is to sell. Whether it is medical care or other industries, this is true, right?"

ps... I was so dizzy that I was a little confused about this chapter. Today I will be updated 2 times and I will go to rest
Chapter completed!